| Autor: |
Erdem Toktay, Muhammet Ali Gürbüz, Tuğba Bal, Özlem Özgül, Elif Erbaş, Rüstem Anıl Ugan, Jale Selli |
| Jazyk: |
English<br />Turkish |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Cukurova Medical Journal, Vol 47, Iss 1, Pp 102-110 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2602-3040 |
| DOI: |
10.17826/cumj.993250 |
| Popis: |
Purpose: In this study, our aim was to investigate the potential effects of strong antioxidant daidzein (DZ) on ovarian ischemia and reperfusion injury. Materials and Methods: A total of 42 female Sprague-Dawley rats were randomly divided into seven groups. For the experimental model, the clamps were removed after 3 hours of ischemia, and blood flow was provided again. Then, reperfusion process was terminated for 3 hours. Daidzein was orally administered to animals at doses of 35 and 70 mg/kg 30 minutes before ischemia (I) and ischemia and reperfusion (I/R) procedures. Results: Severe immunoreactivity of the IL-1β, IL-6 and Caspase-3 were detected in I and I/R groups. Moderate immunoreactivity of IL-1β, IL-6 and Caspase-3 was detected in I+DZ35 and I/R+DZ35 groups, and slightly positivity was detected in I+DZ70 and I/R+DZ70 groups. The SOD activity level increased in the groups treated with Daidzein, while MDA levels decreased. In addition, hemorrhage areas and inflammatory cell migration decreased in I/R+DZ70 and I/R+DZ35 groups, when compared to I/R group in a dose dependent manner. Conclusion: Daidzein has a strong protective role in the treatment of ovarian ischemia-reperfusion injury and can be used as a therapeutic agent. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
